Next Article in Journal
Identification of Two Novel Linear Neutralizing Epitopes within the Hexon Protein of Canine Adenovirus Using Monoclonal Antibodies
Next Article in Special Issue
SARS-CoV-2 mRNA Vaccines: Immunological Mechanism and Beyond
Previous Article in Journal
Peptide Vaccination against Cytomegalovirus Induces Specific T Cell Response in Responses in CMV Seronegative End-Stage Renal Disease Patients
Previous Article in Special Issue
Advancements in mRNA Encoded Antibodies for Passive Immunotherapy

HIV mRNA Vaccines—Progress and Future Paths

Duke Human Vaccine Institute, Duke University School of Medicine, Durham, NC 27710, USA
Department of Immunology, Duke University School of Medicine, Durham, NC 27710, USA
Author to whom correspondence should be addressed.
Academic Editor: Ralph A. Tripp
Vaccines 2021, 9(2), 134;
Received: 13 January 2021 / Revised: 27 January 2021 / Accepted: 2 February 2021 / Published: 7 February 2021
(This article belongs to the Special Issue The Past, Present, and Future of mRNA Vaccines)
The SARS-CoV-2 pandemic introduced the world to a new type of vaccine based on mRNA encapsulated in lipid nanoparticles (LNPs). Instead of delivering antigenic proteins directly, an mRNA-based vaccine relies on the host’s cells to manufacture protein immunogens which, in turn, are targets for antibody and cytotoxic T cell responses. mRNA-based vaccines have been the subject of research for over three decades as a platform to protect against or treat a variety of cancers, amyloidosis and infectious diseases. In this review, we discuss mRNA-based approaches for the generation of prophylactic and therapeutic vaccines to HIV. We examine the special immunological hurdles for a vaccine to elicit broadly neutralizing antibodies and effective T cell responses to HIV. Lastly, we outline an mRNA-based HIV vaccination strategy based on the immunobiology of broadly neutralizing antibody development. View Full-Text
Keywords: HIV; vaccine; messenger RNA HIV; vaccine; messenger RNA
Show Figures

Figure 1

MDPI and ACS Style

Mu, Z.; Haynes, B.F.; Cain, D.W. HIV mRNA Vaccines—Progress and Future Paths. Vaccines 2021, 9, 134.

AMA Style

Mu Z, Haynes BF, Cain DW. HIV mRNA Vaccines—Progress and Future Paths. Vaccines. 2021; 9(2):134.

Chicago/Turabian Style

Mu, Zekun, Barton F. Haynes, and Derek W. Cain. 2021. "HIV mRNA Vaccines—Progress and Future Paths" Vaccines 9, no. 2: 134.

Find Other Styles
Note that from the first issue of 2016, MDPI journals use article numbers instead of page numbers. See further details here.

Article Access Map by Country/Region

Back to TopTop